Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human LDLR Protein, His Tag, 100µg  

Recombinant human LDLR Protein, His Tag, 100µg

Recombinant Human LDLR /LDL Receptor Protein (rhLDLR) Ala 22-Arg788 was produced in human 293 cells (HEK293), His tag

Synonyms: recombinant human protein, LDLR, FH, FHC, LDLCQ2, Low-Density Lipoprotein (LDL) Receptor, LDL receptor protein

More details

LDR-H5224-100

Availability: within 7 days

481,00 €

Background:
Low-Density Lipoprotein (LDL) Receptor, also known as LDLR, FH, FHC, LDLCQ2, and is a mosaic protein of ~840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). It belongs to the Low density lipoprotein receptor gene family. LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis and prevents the LDL just diffusing around the membrane surface. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes ~70% of LDL from the circulation. Synthesis of receptors in the cell is regulated by the level of free intracellular cholesterol; if it is in excess for the needs of the cell then the transcription of the receptor gene will be inhibited. LDL receptors are translated by ribosomes on the endoplasmic reticulum and are modified by the Golgi apparatus before travelling in vesicles to the cell surface. LDL is directly involved in the development of atherosclerosis, due to accumulation of LDL-cholesterol in the blood. Atherosclerosis is the process responsible for the majority of cardiovascular diseases.

Source
Recombinant Human LDLR /LDL Receptor Protein (rhLDLR), His Tag (LDR-H5224) is expressed from human 293 cells (HEK293). It contains AA Ala 22 - Arg 788 (Accession # NP_000518.1).
Predicted N-terminus: Ala 22

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 85.9 kDa. The protein migrates as 120-140 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Improving cardiovascular control in a hypertensive population in primary care. Results from a staff training intervention"
Quester, Björck, Manhem et al
Scand J Prim Health Care (2024)
(2) "The Correlation between Region-specific Epicardial Adipose Tissue and Myocardial Ischemia Defined by CT-FFR in Type 2 Diabetes Mellitus Patients"
Wang, Huang, Wang
Curr Med Imaging (2024)
(3) "Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention"
Ray, Gunn, Conde et al
Atherosclerosis (2024) 391, 117472
Showing 1-3 of 10310 papers.